A class-action lawsuit from thousands of third-party payers alleges that the companies broke racketeering laws to market their diabetes drug Actos, while not disclosing its bladder cancer risk.
https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpacescales4-11-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-06-08 09:00:342023-06-08 09:01:38Lilly, Takeda face class-action racketeering lawsuit over diabetes drug
